Tolemy Bio | $1,643,411 | (May 13, 2026)
Basata | $21,000,000 | (May 13, 2026)
Corvera (YC W26) | $4,200,000 | (May 13, 2026)
Waiv, formerly Owkin Dx
France
- Paris
- 13/03/2026
- Unknown
- $33,000,000
Waiv has evolved to meet this moment:
Hundreds of novel innovations are entering clinical development each year, while biomarker testing complexity and costs are surging. As healthcare undergoes a broader shift toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics.
Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind.
Waiv, a spin-out of Owkin (https://www.owkin.com/), capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC (https://www.owkin.com/diagnostics/rlapsrisk-bc), to unlock morphological insights and future-proof the clinical diagnostic workflow.
- Industry Biotechnology Research
- Website https://wearewaiv.com/
- LinkedIn https://www.linkedin.com/company/we-are-waiv/
4AM | $4,000,000 | (May 13, 2026)
Ciridae | $20,000,000 | (May 13, 2026)
Sedivention - Freezing the hunger feeling | $3,402,541 | (May 13, 2026)
Meatly | $14,074,996 | (May 13, 2026)
NanoStruct GmbH | $3,050,853 | (May 13, 2026)
Adfin | $18,000,000 | (May 13, 2026)
Boundary | $2,000,000 | (May 13, 2026)
Algorithmiq | $21,122,550 | (May 13, 2026)
Knit Health | $11,600,000 | (May 13, 2026)